1cBio, Inc

1cBio is a discovery-stage biopharma company which strives to identify white spaces in cancer therapies and develop molecules that can serve as precision medicines. We focus on defined mechanisms of action which are validated in clinical practice, clinical trials, or preclinical models. Whenever possible our programs are geared to treat the disease and preemptively counter mechanisms for acquired or intrinsic resistance. We combine our core expertise in medicinal chemistry and translational sciences with thought partners in clinical and basic sciences to guide our innovation. Together with our network of research and development partners, our discovery platform is rapidly scalable and easily tailored to suit our current and future needs. Our most advanced programs are an oral ENPP1 inhibitor for hypophosphatasia (HPP) and a selective PARP1 inhibitor. Both programs have started IND-enabling studies. PARP1 is the first program from our emerging portfolio of DDR-related programs which...